미국의 바이오 분석 검사 서비스 시장 규모, 점유율, 동향 분석 보고서 : 분자별, 검사별, 워크플로우별, 최종 용도별, 부문별 예측(2025-2030년)

U.S. Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Molecule (Small Molecule, Large Molecule), By Test, By Workflow, By End-use (Pharma & BioPharma Companies, CDMO, CRO), And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,605,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,051,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,944,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

시장 규모와 동향

미국의 바이오 분석 검사 서비스 시장 규모는 2024년에 19억 8,000만 달러에 달했고, 2025-2030년에 걸쳐 CAGR 9.33%로 성장할 것으로 예측됩니다.

미국의 생물학적 분석 검사 서비스 산업의 성장은 의약품 개발 및 승인 프로세스의 상승, 생물 제제, 바이오시밀러, 유전자 치료 수요 증가, 검사 서비스의 아웃소싱 증가 등, 여러 요인에 의해 초래되고 있습니다.

여러 산업 기업과 바이오 제약 회사는 선진적 바이오 분석 서비스에 대한 수요 증가에 대응하기 위해 검사 인프라의 업그레이드와 확대에 다액의 투자를 실시했습니다. 또한 복잡한 생물 제제, 바이오시밀러, 유전자 치료, 맞춤형 의료 개발의 급증으로 약동학, 바이오마커 탐색, 면역원성 평가와 같은 복잡한 생물학적 분석을 수행할 수 있는 정교한 테스트 플랫폼의 필요성이 더욱 커지고 있습니다.

또한 여러 서비스 제공업체가 고해상도 질량 분석(HRMS), NGS 및 자동화 기술을 통합한 최첨단 시설을 개발하여 보다 빠르고 정확하며 비용 효율적인 바이오 분석 검사를 제공하여 개발을 더욱 촉진하고 있습니다. Laboratory Corporation of America Holdings는 그린필드에 있는 실험실의 확대 완료를 발표했습니다.

바이오 분석 검사의 중요성에 대한 규제 관리와 의식 증가는 바이오 분석 검사 서비스 시장의 성장을 가속하는 주요 요인입니다. 평가에 대한 엄격한 가이드 라인을 도입하면 아웃소싱 지향 증가로 이어졌습니다. 이 지침은 신약 및 바이오시밀러의 안전성과 효능을 향상시키기 위해 정확하고 신뢰할 수 있는 생체 분석 방법의 필요성을 강조합니다. 미국 FDA의 생물분석적 방법 검증 지침은 방법 개발, 검증 및 샘플 분석에 대한 명확한 기준을 제공하며, 이로 인해 제약 회사들은 계약 서비스 제공업체로부터 전문적인 전문 지식을 구하게 되었습니다. 또한, 시장 진출기업은 선진적 분석 플랫폼과 표준화된 프로토콜을 제공하는 것으로, 스폰서가 규제 요건에 준거하는 것을 지원해, 시장 수요를 촉진하고 있습니다.

마찬가지로 기술의 진보와 연구개발투자의 확대도 미국의 생물분석검사 서비스 산업의 성장을 가속하는 주요인입니다. 이러한 혁신은 서비스 제공업체가 보다 복잡한 연구를 수행하고 약물 효능, 안전성, 약동학 등에 대한 정확한 데이터를 얻는 데 도움이 됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 미국의 바이오 분석 검사 서비스 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련 및 보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 투자와 자금 조달의 관점
• 임상 검사 건수 분석(2024년)
  • 지역별 임상 검사 총수(2024년)
  • 임상 검사의 총수(상별)(2024년)
  • 임상 검사의 총수(연구 디자인별)(2024년)
  • 주요 치료 영역별 임상 검사 총수(2024년)
• 가격 모델 분석
• 기술
• 규제 프레임워크
• 시장 분석 도구
  • Porter's Five Forces 분석
  • SWOT 분석에 의한 PESTEL
  • COVID-19의 영향 분석

제4장 미국의 바이오 분석 검사 서비스 시장 : 분자, 추정·동향 분석

• 미국의 바이오 분석 검사 서비스 시장(분자별) : 부문 대시보드
• 미국의 바이오 분석 검사 서비스 시장(분자별) : 변동 분석
• 분자별, 2018-2030년
• 소분자
• 거대분자
  • LC-MS 연구
  • 면역 측정
  • 기타 거대분자 검사

제5장 미국의 바이오 분석 검사 서비스 시장 : 검사, 추정·동향 분석

• 미국의 바이오 분석 검사 서비스 시장(검사별) : 부문 대시보드
• 미국의 생체 분석 검사 서비스 시장(검사별) : 변동 분석
• 검사별, 2018-2030년
• ADME
  • 체내
  • 체외
• 약동학(PK)
• 약역학(PD)
• 바이오 가용성
• 생물학적 동등성
• 바이오마커 검사
• 세포 기반 분석
• 바이러스 검사
• 기타

제6장 미국의 바이오 분석 검사 서비스 시장 : 워크플로우, 추정·동향 분석

• 미국의 바이오 분석 검사 서비스 시장(워크플로우별) : 부문 대시보드
• 미국의 바이오 분석 검사 서비스 시장(워크플로우별) : 변동 분석
• 워크플로우별, 2018-2030년
• 샘플 수집 및 준비
  • 샘플 수집, 취급, 보관
  • 단백질 침전
  • 액액 추출
  • 고상 추출
  • 기타
• 방법 개발 및 검증
• 샘플 분석
  • 하이픈 기법
  • 크로마토그래피 기술
  • 전기영동
  • 리간드 결합 분석
  • 질량 분석
  • 분광기술
  • 유전체과 분자 기술
• 기타

제7장 미국의 바이오 분석 검사 서비스 시장 : 최종 용도별, 추정·동향 분석

• 미국의 바이오 분석 검사 서비스 시장, 최종 용도별 : 부문 대시보드
• 미국의 바이오 분석 검사 서비스 시장, 최종 용도별 : 변동 분석
• 용도별, 2018-2030년
• 제약·바이오 의약품 기업
• CDMO
• 최고경영책임자(CRO)
• 기타

제8장 경쟁 구도

• 시장 진출기업의 분류
• 기업의 시장 점유율/평가 분석, 2024년
• 기업 프로파일
  • Thermo Fisher Scientific, Inc.
  • ICON plc
  • Charles River Laboratories International, Inc.
  • Laboratory Corporation of America Holdings.
  • IQVIA Inc.
  • Syneos Health
  • SGS SA
  • Intertek Group Plc
  • Pace Analytical Services, LLC
  • Medpace Holdings, Inc.
  • North America Science Associates Inc.(NAMSA)

SHW

영문 목차

영문목차

Market Size & Trends:

The U.S. bioanalytical testing services market size was estimated at USD 1.98 billion in 2024 and is expected to grow at a CAGR of 9.33% from 2025 to 2030. The growth of the U.S. bioanalytical testing services industry is driven by several factors, such as the rising drug development and approval process, growing demand for biologics, biosimilars, and gene therapies, and rising outsourcing of testing services. In addition, Stringent FDA regulations are driving the need for precise bioanalytical testing. Furthermore, the expansion of bioanalytical testing facilities is another key aspect driving the market growth.

Several industry players and biopharmaceutical companies are investing significantly to upgrade and expand their testing infrastructure to meet the growing demand for advanced bioanalytical services. Moreover, a surge in the number of complex biologics, biosimilars, gene therapies, and personalized medicine development is further creating the need for sophisticated testing platforms to perform complex bioanalyses, such as pharmacokinetics, biomarker discovery, and immunogenicity assessments.

Moreover, several service providers are developing state-of-the-art facilities integrated with high-resolution mass spectrometry (HRMS), NGS, and automation technologies to offer faster, more accurate, and cost-effective bioanalytical testing, further propelling market progression. For instance, in September 2024, Laboratory Corporation of America Holdings announced the completion expansion of its laboratory in Greenfield. The expansion aimed to o support the development and validation of preclinical and clinical molecular bioanalytical testing services for advanced therapies, including cell and gene therapies for rare diseases, oncology, and other therapeutic areas. This expansion offered a competitive advantage to the firm.

Increasing regulatory control and awareness regarding the importance of bioanalytical testing are key factors propelling the growth of the bioanalytical testing service market. The introduction of stringent guidelines on drug development, particularly in pharmacokinetics, pharmacodynamics, and bioequivalence testing by several regulatory agencies, such as the U.S. FDA and EMA, leads to a rising preference for outsourcing. These guidelines highlight the need for precise and reliable bioanalytical methods to enhance the safety and efficacy of new drugs & biosimilars. For instance, the U.S. FDA's Bioanalytical Method Validation Guidance provides clear standards for method development, validation, and sample analysis, which have driven pharmaceutical companies to seek specialized expertise from contract service providers. Moreover, the market participants assist sponsors in complying with regulatory requirements by offering advanced analytical platforms and standardized protocols, driving market demand.

Likewise, technological advancements and growing R&D investments are key factors driving the U.S. bioanalytical testing service industry growth. The continuous developments of innovative technologies, such as High-Throughput Screening (HTS), Liquid Chromatography-Mass Spectrometry (LC-MS), and Next-generation Sequencing (NGS), have significantly enhanced the precision, speed, and sensitivity of bioanalytical testing. These innovations assist service providers in conducting more complex studies and gaining accurate data on drug efficacy, safety, and pharmacokinetics, among others. Moreover, integrating automation and Artificial Intelligence (AI) into bioanalytical workflows streamlined processes, reduced human error, and improved throughput. Such factors are anticipated to drive the market over the estimated period.

U.S. Bioanalytical Testing Services Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. bioanalytical testing services market report based on molecule, test, workflow, and end-use:

• Molecule Outlook (Revenue, USD Million, 2018 - 2030)
• Small Molecule
• Large Molecule
  • LC-MS Studies
  • Immunoassays
  • Pharmacokinetics (PK)
  • ADA Assay
  • Other immunoassays
  • Other Large Molecule Tests
• Test Outlook (Revenue, USD Million, 2018 - 2030)
• ADME
  • In-vivo
  • In-vitro
• Pharmacokinetics (PK)
• Pharmacodynamics (PD)
• Bioavailability
• Bioequivalence
• Biomarker Testing
• Cell-based Assay
• Virology Testing
• Other Tests
• Workflow Outlook (Revenue, USD Million, 2018 - 2030)
• Sample Collection and Preparation
  • Sample Collection, Handling and Storage
  • Protein Precipitation
  • Liquid-Liquid Extraction
  • Solid Phase Extraction
  • Others
• Method Development and Validation
• Sample Analysis
  • Hyphenated Technique
  • Chromatographic Technique
  • Electrophoresis
  • Ligand Binding Assay
  • Mass Spectrometry
  • Spectroscopic Techniques
  • Nuclear Magnetic Resonance (NMR)
  • Others
  • Genomic and Molecular Techniques
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Others
• Other Processes
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharma & BioPharma Companies
• CDMO
• CRO
• Others

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule
  • 1.2.2. Test
  • 1.2.3. Workflow
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Bioanalytical Testing Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Technological Advancements & Growing R&D Investments
    • 3.2.1.2. Regulatory Control and Increasing Awareness Regarding Bioanalytical Testing
    • 3.2.1.3. Expansion of Bioanalytical Testing Facilities
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Data Security Concerns
• 3.3. Investments & Funding Perspective
• 3.4. Clinical Trials Volume Analysis, (2024)
  • 3.4.1. Total Number Of Clinical Trials By Region (2024)
  • 3.4.2. Total Number Of Clinical Trials, By Phase (2024)
  • 3.4.3. Total Number Of Clinical Trials, By Study Design (2024)
  • 3.4.4. Total Number Of Clinical Trials, By Key Therapeutic Area (2024)
• 3.5. Pricing Model Analysis
• 3.6. Technology Landscape
• 3.7. Regulatory Framework
• 3.8. Market Analysis Tools
  • 3.8.1. Porter's Five Force Analysis
  • 3.8.2. PESTEL by SWOT Analysis
  • 3.8.3. COVID-19 Impact Analysis

Chapter 4. U.S. Bioanalytical Testing Services Market: Molecule Estimates & Trend Analysis

• 4.1. U.S. Bioanalytical Testing Services Market, By Molecule: Segment Dashboard
• 4.2. U.S. Bioanalytical Testing Services Market, By Molecule: Movement Analysis
• 4.3. U.S. Bioanalytical Testing Services Market Estimates & Forecasts, By Molecule, 2018 - 2030 (USD Million)
• 4.4. Small Molecule
  • 4.4.1. Small Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Large Molecule
  • 4.5.1. Large Molecule Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. LC-MS Studies
    • 4.5.2.1. LC-MS Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Immunoassays
    • 4.5.3.1. Immunoassays Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3.2. Pharmacokinetics (PK)
      • 4.5.3.2.1. Pharmacokinetics (PK) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3.3. ADA Assay
      • 4.5.3.3.1. ADA Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3.4. Other
      • 4.5.3.4.1. Other Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Other Large Molecule Tests
    • 4.5.4.1. Other Large Molecule Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Bioanalytical Testing Services Market: Test Estimates & Trend Analysis

• 5.1. U.S. Bioanalytical Testing Services Market, By Test: Segment Dashboard
• 5.2. U.S. Bioanalytical Testing Services Market, By Test: Movement Analysis
• 5.3. U.S. Bioanalytical Testing Services Market Estimates & Forecasts, By Test, 2018 - 2030 (USD Million)
• 5.4. ADME
  • 5.4.1. ADME Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. In-vivo
    • 5.4.2.1. In-vivo Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. In-vitro
    • 5.4.3.1. In-vitro Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Pharmacokinetics (PK)
  • 5.5.1. Pharmacokinetics (PK) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Pharmacodynamics (PD)
  • 5.6.1. Pharmacodynamics (PD) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Bioavailability
  • 5.7.1. Bioavailability Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Bioequivalence
  • 5.8.1. Bioequivalence Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Biomarker Testing
  • 5.9.1. Biomarker Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Cell-based Assay
  • 5.10.1. Cell-based Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Virology Testing
  • 5.11.1. Virology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.12. Other Tests
  • 5.12.1. Other Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Bioanalytical Testing Services Market: Workflow Estimates & Trend Analysis

• 6.1. U.S. Bioanalytical Testing Services Market, By Workflow: Segment Dashboard
• 6.2. U.S. Bioanalytical Testing Services Market, By Workflow Movement Analysis
• 6.3. U.S. Bioanalytical Testing Services Market Estimates & Forecasts, By Workflow, 2018 - 2030 (USD Million)
• 6.4. Sample Collection and Preparation
  • 6.4.1. Sample Collection and Preparation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Sample Collection, Handling and Storage
    • 6.4.2.1. Sample Collection, Handling and Storage Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Protein Precipitation
    • 6.4.3.1. Protein Precipitation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Liquid-Liquid Extraction
    • 6.4.4.1. Liquid-Liquid Extraction Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. Solid Phase Extraction
    • 6.4.5.1. Solid Phase Extraction Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Method Development and Validation
  • 6.5.1. Method Development and Validation Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Sample Analysis
  • 6.6.1. Sample Analysis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Hyphenated Technique
    • 6.6.2.1. Hyphenated Technique Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Chromatographic technique
    • 6.6.3.1. Chromatographic Technique Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. Electrophoresis
    • 6.6.4.1. Electrophoresis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Ligand Binding Assay
    • 6.6.5.1. Ligand Binding Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Mass Spectrometry
    • 6.6.6.1. Mass Spectrometry Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Spectroscopic Techniques
    • 6.6.7.1. Spectroscopic Techniques Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7.2. Nuclear Magnetic Resonance (NMR)
      • 6.6.7.2.1. Nuclear Magnetic Resonance (NMR) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7.3. Others
      • 6.6.7.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.8. Genomic and Molecular Techniques
    • 6.6.8.1. Genomic and Molecular Techniques Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.8.2. Polymerase Chain Reaction (PCR)
      • 6.6.8.2.1. Polymerase Chain Reaction (PCR) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.8.3. Next-Generation Sequencing (NGS)
      • 6.6.8.3.1. Next-Generation Sequencing (NGS) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.8.4. Others
      • 6.6.8.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Other Processes
  • 6.7.1. Other Processes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Bioanalytical Testing Services Market: End Use Estimates & Trend Analysis

• 7.1. U.S. Bioanalytical Testing Services Market, By End Use: Segment Dashboard
• 7.2. U.S. Bioanalytical Testing Services Market, By End Use: Movement Analysis
• 7.3. U.S. Bioanalytical Testing Services Market Estimates & Forecasts, By End Use, 2018 - 2030 (USD Million)
• 7.4. Pharma & BioPharma Companies
  • 7.4.1. Pharma & BioPharma Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. CDMO
  • 7.5.1. CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. CRO
  • 7.6.1. CRO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Share/Assessment Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Thermo Fisher Scientific, Inc.
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. ICON plc
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Charles River Laboratories International, Inc.
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Laboratory Corporation of America Holdings.
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. IQVIA Inc.
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Syneos Health
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. SGS SA
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Intertek Group Plc
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Pace Analytical Services, LLC
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Medpace Holdings, Inc.
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. North America Science Associates Inc. (NAMSA)
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives

관련자료